Omalizumab Treatment in Asthma-COPD Overlap Syndrome
Overview
Pulmonary Medicine
Authors
Affiliations
Introduction: Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is a poorly understood disease with an increasing morbidity and mortality. Currently, the most effective treatment for ACOS is unknown and omalizumab for ACOS has not yet been reported.
Methods: We report our experience with anti-IgE, omalizumab treatment on 3 patients with ACOS as a retrospective case study.
Results: After 1 year of omalizumab treatment, patients experienced significantly lower rates of asthma exacerbation and hospitalization and better asthma control test results.
Conclusion: Our study shows that omalizumab may be an effective and safe therapy for patients with ACOS. However larger randomized trials are needed.
GEMA 5.3. Spanish Guideline on the Management of Asthma.
Plaza Moral V, Alobid I, Alvarez Rodriguez C, Blanco Aparicio M, Ferreira J, Garcia G Open Respir Arch. 2023; 5(4):100277.
PMID: 37886027 PMC: 10598226. DOI: 10.1016/j.opresp.2023.100277.
Asthma-COPD Overlap in Clinical Practice (ACO_CP 2023): Toward Precision Medicine.
Alsayed A, Abu-Samak M, Alkhatib M J Pers Med. 2023; 13(4).
PMID: 37109063 PMC: 10146260. DOI: 10.3390/jpm13040677.
Asthma-COPD Overlap Syndrome: Recent Insights and Unanswered Questions.
Fouka E, Papaioannou A, Hillas G, Steiropoulos P J Pers Med. 2022; 12(5).
PMID: 35629128 PMC: 9146831. DOI: 10.3390/jpm12050708.
Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap.
Ricciardi L, Papia F, Liotta M, Cicero F, Isola S, Tartarisco G Postepy Dermatol Alergol. 2022; 39(1):88-93.
PMID: 35369622 PMC: 8953889. DOI: 10.5114/ada.2022.113804.
Toyota H, Sugimoto N, Kobayashi K, Suzuki Y, Takeshita Y, Ito A Allergy Asthma Clin Immunol. 2021; 17(1):13.
PMID: 33541385 PMC: 7860183. DOI: 10.1186/s13223-021-00514-9.